Cancer Conversations™: PARP Inhibitors in Ovarian Cancer

Get up to date on the most recent developments in leveraging PARP inhibitors to optimally manage ovarian cancer with slides and an on-demand webcast capturing a dynamic Cancer Conversations webinar featuring expert discussion on key areas of consensus and controversy involving the latest data.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.